PARP1 and neoplasm: Over 9 years during which the patient received multiple lines of therapy, the tumor maintained BRCA1 LOH, copy number gains in ABCB10/11, high aneuploidy scores (≥13), MYC amplifications (CN ≥ 10) and PARP1 gains (CN = 4) (Supplementary Fig. 3a).